<DOC>
	<DOCNO>NCT00622505</DOCNO>
	<brief_summary>This study evaluate effectiveness safety dose method zoledronic acid prevent skeletal complication multiple myeloma patient IV bisphosphonate one two year .</brief_summary>
	<brief_title>Zoledronic Acid Treatment ( Every 4 12 Weeks ) Prevent Skeletal Complications Advanced Multiple Myeloma Patients</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Confirmed diagnosis multiple myeloma Have zoledronic acid pamidronate 12 year therapy must initiate osteolytic lesion , bone fracture , spinal compression osteopenia due multiple myeloma Stable renal function Known sensitivity bisphosphonates Receiving investigational drug consider safe coadministration significant effect bone turnover Current active dental problem Had bone marrow transplant blood stem cell transplant within 2 month study entry plan transplant within 2 month follow enrollment Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>skeletal complication</keyword>
	<keyword>bone</keyword>
</DOC>